Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Accumulated Expenses: 2020-2024

Historic Accumulated Expenses for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to $15.8 million.

  • Tarsus Pharmaceuticals' Accumulated Expenses rose 19.66% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year increase of 19.66%. This contributed to the annual value of $15.8 million for FY2024, which is 19.46% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Accumulated Expenses stood at $15.8 million for FY2024, which was up 19.46% from $13.2 million recorded in FY2023.
  • Tarsus Pharmaceuticals' 5-year Accumulated Expenses high stood at $15.8 million for FY2024, and its period low was $1.0 million during FY2020.
  • Its 3-year average for Accumulated Expenses is $11.5 million, with a median of $13.2 million in 2023.
  • Data for Tarsus Pharmaceuticals' Accumulated Expenses shows a peak YoY spiked of 169.04% (in 2021) over the last 5 years.
  • Tarsus Pharmaceuticals' Accumulated Expenses (Yearly) stood at $1.0 million in 2020, then soared by 169.04% to $2.8 million in 2021, then surged by 97.25% to $5.5 million in 2022, then skyrocketed by 139.99% to $13.2 million in 2023, then climbed by 19.46% to $15.8 million in 2024.